Related Experiment Video
Updated: Jun 4, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?
Manfredi Rizzo1, Egle Corrado, Angelo Maria Patti
1Dipartimento di Medicina Interna e Specialistica DIMIS, Universitá di Palermo, Via del Vespro 141, Palermo, Italy. mrizzo@unipa.it
Expert Opinion on Pharmacotherapy
|February 3, 2011
Summary
Cilostazol significantly improves walking distance for intermittent claudication patients. It also favorably impacts atherogenic dyslipidemia by lowering triglycerides and increasing HDL cholesterol.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Metabolic Disorders
Background:
- Cilostazol is a selective PDE3A inhibitor used for intermittent claudication.
- Beyond its known effects, cilostazol influences atherogenic dyslipidemia.
- Its impact on lipid profiles warrants further investigation.
Purpose of the Study:
- To review the effects of cilostazol on plasma lipids, lipoproteins, apolipoproteins, and postprandial lipemia.
- To synthesize current evidence on cilostazol's role in managing dyslipidemia.
- To assess the clinical relevance of these effects in high-risk patients.
Main Methods:
- Comprehensive literature search of Medline and Scopus databases up to October 2010.
- Manual review of references from selected articles.
- Synthesis of findings on cilostazol's impact on lipid metabolism.
Main Results:
- Cilostazol significantly reduces plasma triglyceride levels.
- It leads to a concurrent increase in high-density lipoprotein (HDL) cholesterol.
- Positive effects observed on remnant lipoproteins, HDL subclasses, apolipoprotein B, and postprandial lipemia.
Conclusions:
- Cilostazol improves the pro-atherogenic lipid profile in patients with peripheral arterial disease or type 2 diabetes.
- The drug demonstrates potential in managing atherogenic dyslipidemia.
- Further research is necessary to confirm clinically significant benefits in high-risk populations.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:29Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...